<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319449</url>
  </required_header>
  <id_info>
    <org_study_id>P04060</org_study_id>
    <nct_id>NCT00319449</nct_id>
  </id_info>
  <brief_title>Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)</brief_title>
  <official_title>A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PT. Schering-Plough. Tbk Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe
      10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian
      population with primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - [HDL-C + TG/5]) before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieve the Target LDL-C Concentration of &lt; 3.3 mmol/L (130 mg/dL)</measure>
    <time_frame>6 weeks post treatment</time_frame>
    <description>12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - [HDL-C + TG/5] after treatment for 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg</measure>
    <time_frame>6 weeks post treatment</time_frame>
    <description>12-hour fasting blood samples were collected in participants and the high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol was measured with the basic lipid panel test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 10 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin</description>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin</description>
    <arm_group_label>Placebo 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10 mg</intervention_name>
    <description>10 mg/day atorvastatin, orally, (ongoing treatment in participants)</description>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Placebo 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have an LDL-C concentration &gt;= 3.3 mmol/L (130 mg/dL) to &lt;= 4.9
             mmol/L (190 mg/dL) using the Freidewald calculation.

          -  Participants must have triglyceride concentrations of &lt; 3.99 mmol/L (350 mg/dL).

          -  Participants must have two or more coronary heart disease risk factors listed below:

               -  Current cigarette smoking

               -  Hypertension (BP &gt;= 140/90 mmHg or on antihypertensive medication)

               -  Low HDL cholesterol (&lt; 40 mg/dL)

               -  Family history of premature CHD (CHD in male first degree relative &lt; 55 years;
                  CHD in female first degree relative &lt; 65 years)

               -  Age (Men &gt;= 45 years; women &gt;= 55 years)

          -  Participant must be currently taking atorvastatin 10 mg daily and by history has taken
             80% of daily doses for the 6 weeks prior to participating.

          -  Participants must have liver transaminases (ALT, AST) &lt; 50% above the upper limit of
             normal, with no active liver disease, and CK &lt; 50% above the upper limit of normal.

          -  Participants must have maintained a cholesterol lowering diet, exercise program, and
             stable weight for at least 4 weeks prior to the study and be willing to continue the
             same diet and exercise program during the study.

          -  Women receiving hormonal therapy, including hormone replacement, any estrogen
             antagonist/agonist, or oral contraceptives, must have been maintained on a stable dose
             and regimen for at least 8 weeks and be willing to continue the same regimen for the
             duration of the study.

        Exclusion Criteria:

          -  Participants who meet any of the following criteria will be excluded:

          -  Body mass index (BMI = weight [kg]/height**2[m]) is &gt;= 30 Kg/m**2.

          -  Consume &gt; 14 alcoholic drinks per week.

          -  Women who are pregnant or nursing.

          -  Congestive heart failure defined by NYHA as Class III or IV.

          -  Uncontrolled cardiac arrhythmia.

          -  Coronary heart disease (CHD).

          -  Unstable or severe peripheral artery disease within 3 months of participating

          -  Uncontrolled hypertension (treated or untreated) with systolic blood pressure &gt; 160 mm
             Hg or diastolic &gt; 100 mm Hg.

          -  Type I or Type II diabetes mellitus.

          -  Secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to
             hypothyroidism.

          -  Impaired renal function (creatinine &gt; 2.0 mg/dL) or nephrotic syndrome.

          -  Known HIV positive.

          -  Cancer within the past 5 years (except for successfully treated basal and squamous
             cell carcinomas).

          -  History of mental instability, drug/alcohol abuse within the past 5 years, or major
             psychiatric illness not adequately controlled and stable on pharmacotherapy.

          -  Participants who are on any of the following concomitant medications:

          -  Participants who are on medications that are potent inhibitors of CYP3A4, including
             cyclosporine, systemic itraconazole, fluconazole, and ketoconazole, erythromycin or
             clarithromycin, nefazodone, mibefradil, protease inhibitors and large amounts of
             grapefruit juice (&gt; 1 quart/day).

          -  Participants who are on lipid-lowering agents (other atorvastatin): niacin (&gt; 200
             mg/day)

          -  Participants who are on over the counter lipid lowering agents such as fish oils,
             garlic and cholestin

          -  Participants who are on oral corticosteroids, unless used as replacement therapy for
             pituitary/adrenal disease and the subject is on a stable regimen for at least 6 weeks.

          -  Participants who are currently using psyllium, other fiber-based laxatives, and/or any
             other OTC therapy known to affect serum lipid levels (phytosterol margarine), and have
             not been on a stable regimen for at least 5 weeks and who do not agree to remain on
             this regimen throughout the study.

          -  Participant who are currently using orlistat or sibutramine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Indonesia</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <results_first_submitted>April 14, 2011</results_first_submitted>
  <results_first_submitted_qc>April 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2011</results_first_posted>
  <last_update_submitted>October 9, 2015</last_update_submitted>
  <last_update_submitted_qc>October 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe 10 mg</title>
          <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
        </group>
        <group group_id="P2">
          <title>Placebo 10 mg</title>
          <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject did not wish to continue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with the protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe 10 mg</title>
          <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
        </group>
        <group group_id="B2">
          <title>Placebo 10 mg</title>
          <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="12.1"/>
                    <measurement group_id="B2" value="52.2" spread="10.4"/>
                    <measurement group_id="B3" value="54.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 or older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg</title>
        <description>12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - [HDL-C + TG/5]) before and after treatment.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 10 mg</title>
            <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg</title>
          <description>12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - [HDL-C + TG/5]) before and after treatment.</description>
          <population>Participants who completed the study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.125" lower_limit="130.126" upper_limit="166.124"/>
                    <measurement group_id="O2" value="151.083" lower_limit="136.387" upper_limit="165.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.000" lower_limit="89.030" upper_limit="122.970"/>
                    <measurement group_id="O2" value="108.273" lower_limit="92.923" upper_limit="123.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieve the Target LDL-C Concentration of &lt; 3.3 mmol/L (130 mg/dL)</title>
        <description>12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - [HDL-C + TG/5] after treatment for 6 weeks.</description>
        <time_frame>6 weeks post treatment</time_frame>
        <population>Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 10 mg</title>
            <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieve the Target LDL-C Concentration of &lt; 3.3 mmol/L (130 mg/dL)</title>
          <description>12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - [HDL-C + TG/5] after treatment for 6 weeks.</description>
          <population>Participants who completed the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg</title>
        <description>12-hour fasting blood samples were collected in participants and the high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol was measured with the basic lipid panel test.</description>
        <time_frame>6 weeks post treatment</time_frame>
        <population>Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
          </group>
          <group group_id="O2">
            <title>Placebo 10 mg</title>
            <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg</title>
          <description>12-hour fasting blood samples were collected in participants and the high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol was measured with the basic lipid panel test.</description>
          <population>Participants who completed the study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.250" lower_limit="44.579" upper_limit="61.921"/>
                    <measurement group_id="O2" value="57.667" lower_limit="50.586" upper_limit="67.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.625" lower_limit="43.954" upper_limit="61.296"/>
                    <measurement group_id="O2" value="53.500" lower_limit="46.420" upper_limit="60.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.125" lower_limit="202.355" upper_limit="235.895"/>
                    <measurement group_id="O2" value="226.000" lower_limit="212.307" upper_limit="239.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.375" lower_limit="139.605" upper_limit="173.145"/>
                    <measurement group_id="O2" value="185.667" lower_limit="171.974" upper_limit="199.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.500" lower_limit="105.213" upper_limit="173.787"/>
                    <measurement group_id="O2" value="131.667" lower_limit="103.672" upper_limit="159.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.250" lower_limit="80.963" upper_limit="149.537"/>
                    <measurement group_id="O2" value="120.250" lower_limit="92.255" upper_limit="148.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe 10 mg</title>
          <description>Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
        </group>
        <group group_id="E2">
          <title>Placebo 10 mg</title>
          <description>Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator (PI) agrees not to publish or publicly present
any interim results of the Study without prior written consent of the SPONSOR.
The PI further agrees to provide thirty (30) days written notice to the SPONSOR prior to submission for publication or presentation to allow SPONSOR to review abstracts or manuscripts for publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

